Daiwa Securities Group Inc. Purchases 1,656 Shares of Stryker Corporation $SYK

Daiwa Securities Group Inc. boosted its position in Stryker Corporation (NYSE:SYK) by 2.7% in the 4th quarter, Holdings Channel reports. The firm owned 62,831 shares of the medical technology company’s stock after buying an additional 1,656 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Stryker were worth $22,083,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its stake in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new stake in Stryker in the second quarter worth about $205,000. Marshall Wace LLP lifted its stake in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new stake in Stryker in the second quarter worth about $219,000. Finally, HUB Investment Partners LLC bought a new stake in Stryker in the second quarter worth about $253,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $305.71 on Friday. The firm has a market cap of $117.20 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 1.90 and a beta of 0.78. The company’s 50 day moving average is $318.43 and its 200 day moving average is $345.86. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Leerink Partners decreased their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday. Evercore set a $355.00 price target on shares of Stryker in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Needham & Company LLC decreased their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.